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Background: There have been numerous studies investigating the association between omega-3 fatty
acids (FAs) and depression, with mixed ﬁndings. We propose an approach which is largely free from
issues such as confounding or reverse causality, to investigate this relationship using observational data
from a pregnancy cohort.
Methods: The Avon Longitudinal Study of Parents and Children (ALSPAC) cohort collected information on
FA levels from antenatal blood samples and depressive symptoms at several time points during
pregnancy and the postnatal period. Conventional epidemiological analyses were used in addition to a
Mendelian randomisation (MR) approach to investigate the association between levels of two omega-3
FAs (docosahexaenoic acid (DHA) and eicosapentaenoic acid (EPA)) and perinatal onset depression,
antenatal depression (AND) and postnatal depression (PND).
Results: Weak evidence of a positive association with both EPA (OR¼1.07; 95% CI: 0.99–1.15) and DHA
(OR¼1.08; 95% CI: 0.98–1.19) with perinatal onset depression was found using a multivariable logistic
regression adjusting for social class and maternal age. However, the strength of association was found to
attenuate when using an MR analysis to investigate DHA.
Limitations: Pleiotropy is a potential limitation in MR analyses; we assume that the genetic variants
included in the instrumental variable are associated only with our trait of interest (FAs) and thus cannot
inﬂuence the outcome via any other pathway.
Conclusions: We found weak evidence of a positive association between omega-3 FAs and perinatal onset
depression. However, without conﬁrmation from the MR analysis, we are unable to draw conclusions
regarding causality.
& 2014 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY license
(http://creativecommons.org/licenses/by/3.0/).
1. Introduction
Several studies have investigated the association between omega-3
fatty acids (FAs) and depressive disorders, with mixed results.
Although it has long been established that docosahexaenoic acid
(DHA), a member of the omega-3 family, can affect brain function
and behaviour (Simopoulos, 2009), the precise relationship with
depression is unknown. Evidence from several observational studies
shows an inverse relationship between ﬁsh consumption and depres-
sion which would appear to lend support to this hypothesis, as ﬁsh is
a major source of omega-3 FAs (Hibbeln, 1998, 2002; Tanskanen et al.,
2001; Silvers and Scott, 2002). However, observational studies are
subject to issues such as confounding and reverse causation, and
intervention trials attempting to establish whether depression can be
treated with omega-3 FAs have met with mixed success (Freeman et
al., 2006; Rondanelli et al., 2011; Su et al., 2008; Makrides et al., 2010;
Carney et al., 2009).
It has been suggested that the lack of association in some
intervention studies could be due to the investigation of the wrong
FAs, or even the wrong ratios and dosages of FAs included in the
interventions (Martins, 2009). Alternative criticisms focus on the
broad inclusion criteria around diagnosis and the range of scales
used to measure depression, both of which can lead to a hetero-
geneous mix of cases (Martins et al., 2012; Mischoulon, 2011).
Meta-analyses of these intervention studies fail to reach a con-
sensus on the association between omega-3 FAs and depression
(Appleton et al., 2008, 2010; Bloch and Hannestad, 2012; Martins,
2009; Martins et al., 2012), and difﬁculties arise when attempting
to combine studies due to heterogeneity among the range of study
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designs, types and doses of FAs investigated. Alternative methods
of investigating the relationship between FAs and depression have
not, as of yet, been explored.
It is possible that any association between FA levels and depressive
symptoms are absent other than in challenging conditions, such as
during pregnancy. Due to the increased nutritional demands on the
body and the suspected resultant decrease in levels of highly
unsaturated brain FAs during the antenatal and postnatal periods,
women may be especially at risk of developing depressive symptoms
at this time (Su et al., 2008; Kendall-Tackett, 2010). The potential range
of symptoms and diagnostic criteria used when assessing depression
can result in a heterogeneous mix of cases with varying symptoms,
which can make discovering associations problematic and ﬁndings
difﬁcult to generalise. Perinatal onset depression can be thought of as a
more homogenous subgroup of depression cases. In addition to sex,
these cases are likely to be more similar in terms of age and other
characteristics, as well as all undergoing a similar stress event (i.e.
labour). In this situation, we should have greater power to detect an
association between depression and levels of FAs, assuming such a
relationship exists.
The omega-3 family of FAs are thought to be particularly
relevant to depression as these are involved in brain development
(McNamara and Carlson, 2006; Stahl et al., 2008). In particular,
reduced levels of DHA are associated with impairments in both
cognitive and behavioural performances (Innis, 2007). Alpha-
linolenic acid (ALA) and linoleic acid (LA), from the omega-3 and
omega 6 families respectively, are described as essential FAs
because the body lacks the enzymes to synthesise them and so
both must be obtained through diet. Due to the inefﬁcient
conversion of ALA to the longer chain omega-3 FAs, such as
DHA, an adequate supply of dietary omega-3 FAs is important,
however the modern Western diet tends to consist predominantly
of omega-6 FAs. DHA and arachidonic acid (AA), an omega-6 FA,
are known to be vital during pregnancy for foetal brain develop-
ment, as well as during lactation and throughout the life cycle
(Simopoulos, 2009). During the last trimester, the foetal brain
undergoes rapid growth and requires increased levels of DHA. As
such, maternal FA status is likely to deteriorate while the foetal
demand for DHA is high (Steer et al., 2012; Hornstra, 2000;
Kendall-Tackett, 2010). Eicosapentaenoic acid (EPA) is a precursor
to DHA, and beneﬁcial effects in several conditions, such as
schizophrenia and depression, have been linked to this FA
(Emsley et al., 2002; Marshall and Rathbone, 2011). In studies
investigating the association of omega-3 FAs and depression,
randomised controlled trials have tended to focus on supplemen-
tation with EPA, or EPA administered in parallel with DHA
(Appleton et al., 2010), making it difﬁcult to tease apart the effect
of either FA. Arguments in support of both EPA and DHA as the
more beneﬁcial FA have been put forward, with a meta-analysis by
Martins (2009) concluding that EPA has a greater effect in
alleviating depression. However, other studies have focused on
DHA, given its role as the major FA constituent of brain phospho-
lipids, and the fact that it is the predominant omega-3 FA obtained
through ﬁsh consumption (Sinn et al., 2012; Meyer et al., 2013).
In this study we investigate the association between antenatal
FA levels and perinatal depression using data from the Avon
Longitudinal Study of Parents and Children (ALSPAC) cohort.
ALSPAC is uniquely placed to investigate the causality of any
association with data collected on both FA levels throughout
pregnancy and depressive symptoms at several time points during
pregnancy and the postnatal period. In this study, we use a
Mendelian Randomisation (MR) approach within the analysis to
investigate whether there is a causal link between levels of two
omega-3 FAs (DHA and EPA) and perinatal depression.
MR is a method of assessing causality from observational data
through the use of instrumental variables. MR uses genetic variants, or
scores constructed based on an individual's genotype across several
variants, as a proxy for some modiﬁable risk factor associated with an
outcome of interest, this process is illustrated in Fig. 1. The MR
principle relies on both Mendel's ﬁrst and second laws, which imply
that genotypes transmit across conception to a viable conceptus,
independent of both environment and other genetic variants (Davey
Smith, 2011). Given these assumptions and, assuming the genetic
variants are not associated with the outcome other than through the
risk factor they act as a proxy for, we can make much stronger
inferences about the causal nature of any association between the risk
factor and the outcome (Davey Smith and Ebrahim, 2003). The effects
given by the MR analysis should therefore be free from the problems
of confounding and reverse causality to which observational epide-
miology is prone. To our knowledge, this is the ﬁrst study to
investigate the association between FA levels and depression using
an instrumental variable approach.
2. Methods
2.1. Sample
The ALSPAC study is a prospective cohort located in the South
West of England. All women with an expected due date between
April 1991 and December 1992 were eligible to join the study and
14,541 were initially recruited, resulting in 14,062 live births.
Detailed information was collected on the mothers throughout
pregnancy, and information has continued to be collected on the
children, mothers and partners enroled in the study (Fraser et al.,
2013; Boyd et al., 2013). Details of all available data are contained
on the website through a fully searchable data dictionary (http://
www.bris.ac.uk/alspac/researchers/data-access/data-dictionary/).
(Genetic variant/allelic 
Instrument
risk score)
Modifiable risk factor
(FA levels)
Outcome
(Depression)
Confounders
Fig. 1. Directed acyclic graph illustrating Mendelian randomisation. In this model, allelic risk scores associated with FA levels are calculated and used to assess the
association of both EPA and DHA with perinatal depression.
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Ethical approval for the study was obtained from the ALSPAC Ethics
and Law Committee and the Local Research Ethics Committees.
Women were included in this sample if data were available on
genotype, FA levels and depressive symptoms during pregnancy or
at 8 weeks postnatally. Mothers who lost a child during the neo-
natal period (o28 days after childbirth) and those with a still
birth were excluded from the analysis in order to avoid confound-
ing with bereavement. Mothers with multiple births were also
excluded from the analysis. In order to avoid problems arising
through population stratiﬁcation when using allelic risk scores,
only women with a self-reported ethnicity of White European
were included in the analysis. The total eligible sample size was
therefore 3397 ALSPAC mothers.
2.2. Measures
2.2.1. Edinburgh Postnatal Depression Scale
The Edinburgh Postnatal Depression Scale (EPDS) (Cox et al.,
1987) was used to measure depressive symptoms at several time
points during pregnancy and after childbirth. Although initially
developed for use in the postnatal period, the EPDS has been
validated for use both during pregnancy and following childbirth
(Murray and Cox, 1990; Adouard et al., 2005). A threshold of 412
has been shown to highlight participants likely to be suffering
from a depressive illness (Cox et al., 1987). This cut off is in
accordance with that recommended by Cox et al. (1987).
Three sub-groups of depression were investigated; these were
perinatal onset depression, antenatal depression (AND) and post-
natal depression (PND). Womenwere deﬁned as having a perinatal
onset of depression if they were not depressed at 18 weeks
gestation but went on to develop depressive symptoms at either
32 weeks gestation or 8 weeks postnatally. A score of 412 on the
EPDS was used to deﬁne presence of depressive symptoms. PND
and AND were deﬁned according to EPDS scores at a single time
point. Women were assigned PND case or control status according
to responses given in questionnaires completed at approximately
8 weeks postnatally, those scoring 412 were classed as cases.
AND was calculated by applying the same threshold to responses
given at around 32 weeks gestation.
2.2.2. Levels of docosahexaenoic acid and eicosapentaenoic acid
FA levels were extracted from antenatal blood samples col-
lected from the mothers. Blood samples were taken at least once
during pregnancy for FA composition analysis from 5222 mothers.
The FA composition analysis has previously been described in
detail by Newson et al. (2004). FA levels reported here refer to EPA
or DHA as a proportion of the total FAs extracted from red blood
cell (RBC) membrane phospholipids. The change in DHA levels
refer to increments of 1%, while increments of 0.1% are used for
EPA; for example a 3 unit change in DHA levels would correspond
to a 3% change in DHA as a proportion of total RBC membrane FAs,
while a 3 unit change in EPA would refer to a 0.3% change in EPA as
a proportion of total RBC membrane FAs.
2.3. Genotype data
Genotyping was carried out at the Centre National de Géno-
typage (CNG) using the Illumina Human660W-quad array. Quality
control measures included the removal of single nucleotide poly-
morphisms (SNPs) with 45% missing information, minor allele
frequency (MAF) o1% and deviation from Hardy–Weinberg
equilibrium (HWE) (po1.0106). Excluded individuals were
those with 45% missing information, evidence of non-European
ancestry from principal component analysis of the GWAS data or
indeterminate X chromosome heterozygosity. A total of 8340
subjects and 526,688 SNPs passed these quality control ﬁlters.
2.4. Allelic risk scores
Allelic risk scores were calculated using results reported in
Lemaitre et al. (2011), a GWAS of omega-3 FAs which did not include
the ALSPAC sample. SNPs located on either chromosome 6 or 11
associated with po5106 were reported and where groups of SNPs
were in high LD, the most signiﬁcant of these was used to calculate the
score, thus including only independent signals in the calculation. The
‘risk’ allele included in the score was that associated with a decrease in
the relevant FA. Risk scores were calculated for each of DHA and EPA
as a weighted sum of the number of risk alleles according to an
individual's genotype across the relevant SNPs, and the effect sizes
given by Lemaitre et al. (2011).
Locus zoom plots (Pruim et al., 2010) were used to visualise the
LD structure between the SNPs reported in Lemaitre et al. (2011).
Regions in LD (r240.7) were identiﬁed and the most signiﬁ-
cant SNP from each group was noted for use in the score
(Supplementary Table 1).
2.5. Analysis
Analyses were carried out using Stata 12 (Statacorp, 2011).
Initially the observational associations between perinatal onset
depression and DHA and EPA were examined using logistic
regression. Potential confounders were considered a priori and
associations with depression and the FAs were investigated using
chi-squared tests, t-tests and correlations (or a non-parametric
equivalent). The potential confounding variables included mater-
nal age, alcohol consumption during pregnancy, pre-pregnancy
BMI, maternal social class and parity. Variables found to be
signiﬁcantly associated with both case status and FA level, or
which were considered necessary to adjust for a priori, were
considered for inclusion in the multivariable model.
The univariable models were restricted to mothers with complete
data on all covariates included in the ﬁnal multivariable model.
In a second step, 2 stage least squares regression (2SLS) was used
in order to carry out the MR analyses. Allelic risk scores were
calculated and used as instruments for EPA and DHA. The 2SLS
method is generally intended for use with a continuous outcome. In
the case of our binary depression outcomes, the results are still valid
provided robust standard errors are used. Unlike the logistic regression
which provides results in the form of odds ratios, the MR analysis
presents results in terms of risk differences (RD). In order to make the
MR estimates comparable to those calculated for the observational
associations, risk differences were also calculated for these associations
(Supplementary Table 2). A test of endogeneity was performed to test
for differences between the estimates calculated using both the MR
and conventional approaches.
The strength of the instrumental variables (IVs) used in the
analysis was assessed using the Staiger-Stock rule of thumb in
which instruments with an F-statistic of 10 or less are generally
deemed to be weak instruments (Staiger and Stock, 1997).
2.6. Secondary analyses
Secondary analyses looked at the association between PND and
AND with levels of EPA and DHA, using the same method of
analysis described previously. Evidence of a non-linear relation-
ship between FA levels and perinatal onset depression was also
investigated. First, women in the lowest quartile of each FA were
compared with the remaining women; in a further model, a
quadratic term (the square of the FA level) was added into
the model.
H. Sallis et al. / Journal of Affective Disorders 166 (2014) 124–131126
3. Results
3.1. Sample characteristics
The sample consisted of 306 mothers (11.5%) with a perinatal
onset of depression, and 2357 controls who did not develop
depressive symptoms either throughout pregnancy or by 8 weeks
postnatally (Table 1). The number of mothers in the AND (pre-
valent antenatal cases) and PND (prevalent postnatal cases) sub-
groups were 441 (13.2%) and 265 (8.4%) respectively. The
distribution of EPA was positively skewed, with 2 extreme obser-
vations among the controls exceeding 2%. These were excluded
from the analysis as outliers, after which the mean value of EPA
was 0.27% (SD¼0.16). DHA showed less skew than EPA, and had a
mean value of 2.31% (SD¼1.33).
Among our sample, the mean maternal age at delivery was 28.9
years (SD¼4.5) and the majority of women were among the
higher social classes with only 9.9% falling in the lower (IV/V)
category. In our sample, 81.8% of mothers breast fed at some point
within the ﬁrst 4 weeks of childbirth (Table 1).
Of the potential confounders investigated, there was evidence
of an association between perinatal onset depression and both
social class and maternal age at delivery (Table 2). FA levels
showed an association with birth weight (EPA only), pre-
pregnancy BMI, social class and maternal age at delivery (Table 3).
3.2. Allelic risk scores
The risk scores for both EPA and DHA were calculated from
SNPs located on chromosomes 6 and 11 in the region of the FADS
and ELOVL genes; the score for EPA was comprised of 23 SNPs
while the score for DHA included 4 SNPs (for details, see
Supplementary Table 1). Although the correlation was small, there
was evidence of an association between DHA levels and the
corresponding risk score (r¼0.071, p¼0.002), however there was
very weak evidence of association between EPA levels and the
allelic risk score (r¼0.016, p¼0.402). As a result, IV analysis of EPA
would be subject to extreme weak instrument bias and as such we
only report results of the IV analysis performed for DHA.
3.3. Perinatal onset depression
An unadjusted logistic regression of perinatal onset depression
on EPA found no strong evidence of an association in our sample
(n¼2377, OR¼1.05 [0.98,1.13]), the same also occurred when
looking at DHA (n¼2378, OR¼1.06 [0.97,1.16]). After adjusting
for social class and maternal age, the associations increased
marginally, and showed weak evidence of an association with
both EPA (OR¼1.07 [0.99,1.15]) and DHA (OR¼1.08 [0.98,1.19])
(Table 4).
Table 1
Perinatal onset depression sample characteristics.
PoD Casesa (n¼306) Controls (n¼2357) Overall
EPA – mean % (SD) 0.28 (0.17) 0.27 (0.16) 0.27 (0.16)
DHA – mean % (SD) 2.38 (1.38) 2.30 (1.33) 2.31 (1.33)
Birth weight – mean kg (SD)b 3.43 (0.50) 3.47 (0.50) 3.46 (0.50)
Maternal age at delivery (SD) 28.2 (4.5) 29.0 (4.4) 28.9 (4.5)
Pre-pregnancy BMI (SD)c 23.0 (4.8) 22.8 (3.5) 22.9 (3.7)
Gender of child – n (%)
Male 157 (51.3) 1156 (49.1) 1313 (49.3)
Female 149 (48.7) 1201 (50.9) 1350 (50.7)
Breast feedingd – n (%)
No 77 (25.8) 397 (17.2) 474 (18.2)
Yes 222 (74.2) 1914 (82.8) 2136 (81.8)
Social classe – n (%)
High (I/II) 84 (31.5) 864 (40.9) 948 (39.9)
Mid (III) 149 (55.8) 1045 (49.5) 1194 (50.2)
Low (IV/V) 34 (12.7) 202 (9.6) 236 (9.9)
Parityf – n (%)
0 135 (44.7) 1100 (47.1) 1235 (46.8)
1 105 (34.8) 837 (35.8) 942 (35.7)
2þ 62 (20.5) 401 (17.1) 463 (17.5)
Alcohol consumption during pregnancyg – n (%)
0 units 144 (68.2) 1104 (66.5) 1248 (66.7)
1–4 units 40 (19.0) 388 (23.3) 428 (22.9)
5þ units 27 (12.8) 169 (10.2) 196 (10.5)
aPoD¼Perinatal onset depression.
Missing data: bBirth weight – 29, cPre-pregnancy BMI – 193, dBreast feeding – 53, eSocial class – 285, fParity – 23, gAlcohol consumption – 791 (questions relating to
alcohol consumption were included from 15/07/91).
Table 2
Univariable associations with perinatal onset depression.
PoDa OR 95% CI p value N
Birth weight (kg) 0.88 0.69,1.11 0.275 2634
Maternal age at delivery 0.96 0.93,0.99 0.004 2663
Pre-pregnancy BMI 1.01 0.98,1.05 0.528 2470
Social class
Mid (III) 1.47 1.11,1.94 0.008 2378
Low (IV/V) 1.73 1.13,2.65
Parity
1 1.02 0.78,1.34 0.357 2640
2þ 1.26 0.91,1.74
Alcohol consumption
1–4 units 0.79 0.55,1.14 0.232 1872
5þ units 1.22 0.79,1.91
a PoD¼perinatal onset depression.
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Using the 2SLS approach, the association with DHA attenuated
and there was no longer evidence of an association when adjusting
for social class and maternal class (RD¼0.08 [0.05,0.21])
(Table 5). The estimates calculated in the MR and the observational
analysis were not found to differ when performing a test of
endogeneity (p¼0.230). An assessment of instrument strength
indicates that the IV used for DHA was of an acceptable level
(F¼12.01).
3.4. Antenatal depression
Unadjusted logistic regression showed no association between
either EPA (OR¼0.95 [0.89,1.02]) or DHA (OR¼0.96 [0.88,1.05])
with AND. A model adjusting for social class and maternal age
again found no strong evidence of an association with either of
the FAs and AND (EPA: OR¼0.97 [0.91,1.04], DHA: OR¼0.99
[0.91,1.07]) (Table 4).
The MR analysis of DHA shows a similar trend (unadjusted:
RD¼0.07 [0.08,0.22], adjusted: RD¼0.05 [0.09,0.19]) and
found no robust evidence of an association with AND (Table 5).
Once again a test of endogeneity found no substantial difference
between the estimates from the MR and the observational ana-
lyses (p¼0.440). The instrument for DHA remained of an accep-
table strength (F¼11.97).
3.5. Postnatal depression
A logistic regression of PND on EPA showed no substantial
evidence of association either in an unadjusted model or when
adjusting for social class and maternal age (unadjusted OR¼1.04
[0.96,1.12]; adjusted OR¼1.04 [0.96,1.13]). This pattern remained
when analysing the association between PND and DHA (unad-
justed OR¼1.03 [0.95,1.12]; adjusted OR¼1.03 [0.93,1.14])
(Table 4).
Again, the MR analysis found no robust evidence of an associa-
tion between DHA and PND (unadjusted RD¼0.03 [0.08,0.14];
adjusted RD¼0.02 [0.08,0.13]) (Table 5). As in the previous
analyses, the estimates from the MR and the observational analysis
were not found to differ (p¼0.700). The strength of the DHA IV
remained a suitable strength for use in the analysis (F¼14.53).
3.6. Non-linearity
There was no robust evidence of a non-linear association
between levels of either FA and depression. This remained the
case when social class and maternal age at delivery were
adjusted for.
Table 3
Univariable associations with omega-3 FA levels (% total RBC phospholipid FAs) –PoD1 controls only.
FA Beta 95% CI p value N
Birth weight EPA 0.18 0.31,0.05 0.008 2327
DHA 0.06 0.17,0.04 0.245 2329
Alcohol consumption EPA 1–4 units 0.07 0.12,0.25 0.187 1660
5þ units 0.24 0.02, 0.50
DHA 1–4 units 0.13 0.03,0.28 0.155 1661
5þ units 0.15 0.07,0.37
Pre-pregnancy BMI EPA 0.03 0.05, 0.01 0.004 2190
DHA 0.02 0.04,0.01 0.002 2192
Parity EPA 1 0.11 0.26,0.03 0.321 2336
2þ 0.06 0.24,0.13
DHA 1 0.13 0.25,0.01 0.112 2338
2þ 0.03 0.18,0.12
Social class EPA Mid (III) 0.149 0.297,0.002 o0.001 2110
Low (IV/V) 0.500 0.750,0.249
DHA Mid (III) 0.148 0.27,0.03 o0.001 2111
Low (IV/V) 0.44 0.65,0.24
Maternal age at delivery EPA 0.03 0.01,0.04 o0.001 2355
DHA 0.02 0.01,0.03 o0.001 2357
1 PoD¼perinatal onset depression.
Table 4
Logistic regression of depression on omega-3 FA levels (% total RBC
phospholipid FAs).
OR 95% CI p value N
Unadjusted model
EPA
Perinatal onset 1.05 0.98,1.13 0.168 2377
Antenatal depression 0.95 0.89,1.02 0.168 2911
Postnatal depression 1.03 0.95,1.12 0.417 2756
DHA
Perinatal onset 1.06 0.97,1.16 0.204 2378
Antenatal depression 0.96 0.88,1.05 0.360 2912
Postnatal depression 1.03 0.93,1.14 0.570 2757
Adjusted modela
EPA
Perinatal onset 1.07 0.99,1.15 0.083 2377
Antenatal depression 0.97 0.91,1.04 0.439 2911
Postnatal depression 1.04 0.96,1.13 0.301 2756
DHA
Perinatal onset 1.08 0.98,1.19 0.102 2378
Antenatal depression 0.99 0.91,1.07 0.752 2912
Postnatal depression 1.04 0.94,1.15 0.421 2757
a Adjusted for social class (I/II, III or IV/V) and maternal age.
Table 5
IV regression of depression on DHA levels (% total RBC phospholipid FAs).
RDa 95% CI p value Endogeneity
test – p value
N
Unadjusted model
Perinatal depression 0.09 0.05,0.23 0.204 0.202 2378
Antenatal depression 0.07 0.08,0.22 0.377 0.328 2912
Postnatal depression 0.03 0.08,0.14 0.608 0.630 2757
Adjusted modelb
Perinatal onset 0.08 0.05,0.22 0.214 0.230 2378
Antenatal depression 0.05 0.09,0.19 0.464 0.440 2912
Postnatal depression 0.02 0.08,0.13 0.660 0.700 2757
a RD¼Risk difference.
b Adjusted for social class (I/II, III or IV/V) and maternal age.
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4. Discussion
When using logistic regression, a conventional observational
approach to the analysis, we found weak evidence of an associa-
tion between both EPA and DHA with perinatal onset depression.
By including only womenwho were without depressive symptoms
at the beginning of pregnancy, we have selected those who
developed depression during a time when FA status is likely to
be depleted - the potentially ‘pure’ cases of depression onset due
to pregnancy. Mothers without depressive symptoms at the start
of their pregnancy may have been initially less vulnerable to
depression, and the change in FA status could have been the
trigger for their development of depressive symptoms. If omega-3
FAs are associated with increased vulnerability to depression, then
it seems plausible that this association would be more apparent
among women who were otherwise at a lower risk for the
disorder. The results of the analysis suggest that higher, rather
than lower, levels of FAs are associated with an increased vulner-
ability to perinatal onset depression. The analysis provided weak
evidence that a 0.1% increase in EPA was associated with a 6%
increased odds of a perinatal onset, while a 1% increase in DHA
was associated with an 8% increase in odds of perinatal onset
depression. This is in contrast to our initial expectation that a
reduction in FAs could lead to an increase in depressive symptoms.
When investigating women with a perinatal onset, the sample
size is around 2378. The analysis of AND and PND, regardless of
the timing of onset, gives us a slightly larger sample size (n¼2912
and 2757), however among these groups we found no evidence of
association. The combination of perinatal onset cases with women
who were depressed throughout, thus including those in whom
the onset was unrelated to pregnancy, could go some way to
explaining the lack of association found among the AND and PND
groups. Although the MR analysis shows no robust association
even among the subset of women with a perinatal onset, much
larger sample sizes are required for this approach to the analysis to
be adequately powered. As a result, it is perhaps unsurprising that
no association was found using the 2SLS method. For both the
AND and PND groups, the MR analysis conﬁrms the results shown
in the simple logistic regression, in that there was no association
found between either of the omega-3 FAs and depression. How-
ever, this may give us more conﬁdence that there is no strong
association present in the dataset that is being masked by
confounding.
Although many studies have attempted to unpick the associa-
tion between FA levels and depression before, to our knowledge
this is the ﬁrst to do so using an MR approach. ALSPAC is a unique
resource in that it has available data on blood FA levels, genotyp-
ing data and information on depression at multiple times point
during the perinatal period. Previous studies have differed greatly
in the combination of FAs investigated, the doses and methods of
intervention, which makes them difﬁcult to combine in a pooled
analysis. Here, we attempted to investigate causality using obser-
vational data available from a large sample of pregnant women. In
order to have adequate power to detect an effect, should one be
present, the MR analysis would require replication in a much
larger sample.
4.1. Strengths and limitations
A main strength of our study is that the ALSPAC study is a large
prospective cohort collecting detailed information on a variety of
areas; in addition to this we also have genetic data and biomarkers
available on a large subset of these women. In this study our total
eligible sample size was 3397 women, a relatively large sample
with which to investigate the association of omega-3 FAs and
perinatal depression.
A further strength of the analysis is that we have data available
on the levels of both FAs we are interested in, rather than having
to rely on a proxy measure, such as supplements or self-reported
food frequency questionnaires. Additionally, the FAs used in the
analysis were RBC phospholipids, which are a better measure of
longer term dietary habits than plasma phospholipids, which are
sensitive to recent intake (Sun et al., 2007). RBC phospholipids
reﬂect dietary intake over the previous months, whereas plasma
phospholipids would measure intake in the previous days or
weeks. Given that this measure is more stable, our allelic risk
score is therefore likely to be a better instrument for this than it
would for a more frequently ﬂuctuating measure given that non-
fasting blood samples were used.
Another additional strength of this analysis is that the MR
approach enables us to investigate associations free from issues of
confounding and reverse causation, which are so often proble-
matic in observational epidemiology. Under the MR assumptions,
application of this technique can strengthen our conﬁdence in
conclusions when making causal inferences.
There are also several limitations with the current study which
warrant discussion. Firstly, pleiotropy is always a potential pro-
blem when using genetic variants as IVs, when using an allele
score this problem is magniﬁed as there are more variants that
could be pleiotropic. Pleiotropy occurs when a SNP is associated
with several traits, rather than just the trait of interest. If this is the
case, then the assumptions of the MR analysis could be violated if
the risk score is associated with depression via traits other than
the omega-3 FAs in question. In this case, it seems possible that
the score could be associated with other FAs. The correlation
between our FAs of interest, EPA and DHA, is fairly strong at 0.725
(po0.001). Both FAs show signals in the regions of ELOVL2 on
Chromosome 6 and the FADS gene cluster on Chromosome 11
(Lemaitre et al., 2011). This is also the case for docosapentaenoic
acid (DPA), another member of the omega-3 family, while ALA,
another omega-3 FA, and many of the omega-6 family are
primarily associated with the FADS gene cluster. Thus it could be
that any association we see is due to a FA other than those we have
investigated, or even a combination of FAs.
The allele score constructed here for DHA is more speciﬁc to
this FA than to other FAs on the omega-3 pathway, however, given
that the FAs themselves are so interlinked, it is difﬁcult to tease
apart their effects and it is likely that any score will correlate,
albeit to a lesser extent, with other omega-3 FAs. However, this is a
general concern when looking at FAs rather than a limitation
speciﬁc to this study.
Additionally, the time at which samples were taken could also
be thought of as a limitation. Blood samples were taken through-
out pregnancy; however there were higher levels of missing data
at the beginning of pregnancy. In an attempt to make the FAs more
comparable in terms of gestation, the measurement used in the
analysis was the FA level extracted from the last blood sample
taken. A sensitivity analysis controlling for gestation at which the
FA measurement was collected showed a negligible difference
between the results of the two models.
In addition to the limitations with our FA exposure variable,
the depression outcome variable also presents some challenges.
Psychiatric outcomes are notoriously difﬁcult to deﬁne, cases can
present with a whole range of symptoms, which can make
associations harder to establish. In our sample, cases were
chosen based on a self-reported scale and thresholds were used
to distinguish mothers most likely to be suffering a depressive
disorder, rather than being based on a clinical diagnosis.
Although the EPDS has been widely validated and shown to
perform well, using cases based on a clinical diagnosis could
potentially have increased our power to detect any association
present.
H. Sallis et al. / Journal of Affective Disorders 166 (2014) 124–131 129
Finally, although our eligible sample size was large, the use of
IV methods requires very large numbers in order to have power to
detect an effect, and so our MR analysis may still be lacking in
power. A crude estimate, based on the reduction in standard errors
that would be necessary to detect an effect of the magnitude of
our estimates, points to an increase in sample size of around
4 times the current number (Wooldridge, 2002). Although the IV
for DHAwas found to be of a suitable strength, the score calculated
for EPA was too weak to act as an effective instrument for EPA
levels in our sample.
5. Conclusion
In conclusion, we found a weak association between increased
omega-3 FA levels and perinatal onset depression in our sample
when adjusting for maternal age and social class. However, these
associations attenuated when using an MR approach and so we are
unable to make inferences surrounding causality. When looking at
PND and AND, we found no robust association with either of the
omega-3 FAs investigated.
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